Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 3,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Solid Tumor (Phase I) Clear all
Terminated Phase 1 Interventional

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

NCT00311558
View directory record Official record
Conditions
Cancer
Interventions
recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

NCT02222363
View directory record Official record
Conditions
Refractory Cancer
Interventions
VLX600
Drug
Lead sponsor
Vivolux AB
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

NCT05309187
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
IO-202, IO-202 + pembrolizumab combination therapy, RP2D of IO-202 + pembrolizumab combination therapy in multiple solid tumor types
Biological
Lead sponsor
Immune-Onc Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01106599
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0623
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

NCT00521144
View directory record Official record
Conditions
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Dose-Escalation Safety and Pharmacokinetic Study of Iso-Fludelone in Patients With Advanced Solid Tumors

NCT01379287
View directory record Official record
Conditions
Solid Tumors
Interventions
Iso-Fludelone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

First-in-Human Study of TAK-280 in Participants With Solid Tumors

NCT05220098
View directory record Official record
Conditions
Unresectable Locally Advanced or Metastatic Cancer
Interventions
TAK-280
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • San Francisco, California • Minneapolis, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Early Phase 1 Interventional

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

NCT04237649
View directory record Official record
Conditions
Solid Tumors
Interventions
KAZ954, PDR001, NIR178, NZV930
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

NCT03386526
View directory record Official record
Conditions
Advanced Solid Tumors or Hematologic Malignancies
Interventions
APG-1387 for Injection
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Ann Arbor, Michigan • Grand Rapids, Michigan • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

NCT00161187
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2015 · Synced Oct 18, 2026, 9:12 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

NCT03530397
View directory record Official record
Conditions
Selected Advanced Solid Tumors
Interventions
MEDI5752, Pemetrexed, Carboplatin, Pembrolizumab, Paclitaxel or Nab-Paclitaxel
Biological · Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Detroit, Michigan • New York, New York • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1Phase 2 Interventional

Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor

NCT00004159
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1Phase 2 Interventional

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

NCT06257758
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Breast Cancer, Recurrent Ovarian Cancer, Prostate Cancer
Interventions
VIO-01
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Lake Mary, Florida • Oklahoma City, Oklahoma • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional Results available

Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection

NCT00668382
View directory record Official record
Conditions
Neoplasm Metastases
Interventions
Alpha-Gal Glycosphingolipid
Biological
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2013 · Synced Oct 18, 2026, 9:12 PM EDT
Recruiting Phase 1 Interventional

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368
View directory record Official record
Conditions
Solid Tumors, Adult
Interventions
DCR-PDL1
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Irving, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

NCT00187174
View directory record Official record
Conditions
Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
Interventions
Everolimus
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

NCT00104962
View directory record Official record
Conditions
Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement

NCT00882180
View directory record Official record
Conditions
Solid Tumors
Interventions
ALN-VSP02
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
7
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

NCT03422679
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL
Interventions
CB-103
Drug
Lead sponsor
Cellestia Biotech AG
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
3
States / cities
Santa Monica, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Oct 18, 2026, 9:12 PM EDT
Terminated Phase 1 Interventional

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

NCT05036291
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
NB004 tablets
Drug
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
New Orleans, Louisiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1Phase 2 Interventional Results available

AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy

NCT02694822
View directory record Official record
Conditions
Advanced Solid Cancers, Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies
Interventions
Zalifrelimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
11
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas

NCT02076451
View directory record Official record
Conditions
Advanced Solid Tumor, Lymphoma
Interventions
DS-8273a
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

NCT00920257
View directory record Official record
Conditions
Cancer
Interventions
GSK2141795
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
6
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 18, 2026, 9:12 PM EDT
Completed Phase 1 Interventional

Octreotide and Doxorubicin in Treating Patients With Advanced Cancer

NCT00008073
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
doxorubicin hydrochloride, octreotide acetate
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 18, 2026, 9:12 PM EDT